Cl	B:C3501592
-	I:C3501592
NQTrp	I:C3501592
Alleviates	O
Tauopathy	O
Symptoms	O
in	O
a	O
Model	O
Organism	I:C0012644
through	O
the	O
Inhibition	O
of	O
Tau	O
Aggregation	O
-	O
Engendered	O
Toxicity	O
.	O

Cl	O
-	I:C3501592
NQTrp	I:C3501592
Alleviates	O
Tauopathy	B:C0949664
Symptoms	O
in	O
a	O
Model	O
Organism	I:C0012644
through	O
the	O
Inhibition	O
of	O
Tau	O
Aggregation	O
-	O
Engendered	O
Toxicity	O
.	O

Cl	O
-	I:C3501592
NQTrp	I:C3501592
Alleviates	O
Tauopathy	O
Symptoms	B:C1457887
in	O
a	O
Model	O
Organism	I:C0012644
through	O
the	O
Inhibition	O
of	O
Tau	O
Aggregation	O
-	O
Engendered	O
Toxicity	O
.	O

Cl	O
-	I:C3501592
NQTrp	I:C3501592
Alleviates	O
Tauopathy	O
Symptoms	O
in	O
a	O
Model	B:C0012644
Organism	I:C0012644
through	O
the	O
Inhibition	O
of	O
Tau	O
Aggregation	O
-	O
Engendered	O
Toxicity	O
.	O

Cl	O
-	I:C3501592
NQTrp	I:C3501592
Alleviates	O
Tauopathy	O
Symptoms	O
in	O
a	O
Model	O
Organism	I:C0012644
through	O
the	O
Inhibition	O
of	O
Tau	B:C0085401
Aggregation	O
-	O
Engendered	O
Toxicity	O
.	O

Cl	O
-	I:C3501592
NQTrp	I:C3501592
Alleviates	O
Tauopathy	O
Symptoms	O
in	O
a	O
Model	O
Organism	I:C0012644
through	O
the	O
Inhibition	O
of	O
Tau	O
Aggregation	B:C3850147
-	O
Engendered	O
Toxicity	O
.	O

Cl	O
-	I:C3501592
NQTrp	I:C3501592
Alleviates	O
Tauopathy	O
Symptoms	O
in	O
a	O
Model	O
Organism	I:C0012644
through	O
the	O
Inhibition	O
of	O
Tau	O
Aggregation	O
-	O
Engendered	O
Toxicity	B:C0600688
.	O

Alzheimer	B:C0002395
's	I:C0002395
disease	I:C0002395
(	O
Alzheimer	O
's	I:C0002395
disease	I:C0002395
)	O
is	O
the	O
most	O
abundant	O
tauopathy	O
and	O
is	O
characterized	O
by	O
Aβ	O
-	O
derived	O
plaques	O
and	O
tau	O
-	O
derived	O
tangles	O
,	O
resulting	O
from	O
the	O
unfolding	O
of	O
the	O
corresponding	O
monomeric	O
subunits	I:C0599220
into	O
ordered	O
β-	O
sheet	I:C0162806
oligomers	O
and	O
fibrils	O
.	O

Alzheimer	O
's	I:C0002395
disease	I:C0002395
(	O
Alzheimer	B:C0002395
's	I:C0002395
disease	I:C0002395
)	O
is	O
the	O
most	O
abundant	O
tauopathy	O
and	O
is	O
characterized	O
by	O
Aβ	O
-	O
derived	O
plaques	O
and	O
tau	O
-	O
derived	O
tangles	O
,	O
resulting	O
from	O
the	O
unfolding	O
of	O
the	O
corresponding	O
monomeric	O
subunits	I:C0599220
into	O
ordered	O
β-	O
sheet	I:C0162806
oligomers	O
and	O
fibrils	O
.	O

Alzheimer	O
's	I:C0002395
disease	I:C0002395
(	O
Alzheimer	O
's	I:C0002395
disease	I:C0002395
)	O
is	O
the	O
most	O
abundant	O
tauopathy	B:C0949664
and	O
is	O
characterized	O
by	O
Aβ	O
-	O
derived	O
plaques	O
and	O
tau	O
-	O
derived	O
tangles	O
,	O
resulting	O
from	O
the	O
unfolding	O
of	O
the	O
corresponding	O
monomeric	O
subunits	I:C0599220
into	O
ordered	O
β-	O
sheet	I:C0162806
oligomers	O
and	O
fibrils	O
.	O

Alzheimer	O
's	I:C0002395
disease	I:C0002395
(	O
Alzheimer	O
's	I:C0002395
disease	I:C0002395
)	O
is	O
the	O
most	O
abundant	O
tauopathy	O
and	O
is	O
characterized	O
by	O
Aβ	O
-	O
derived	O
plaques	B:C0333463
and	O
tau	O
-	O
derived	O
tangles	O
,	O
resulting	O
from	O
the	O
unfolding	O
of	O
the	O
corresponding	O
monomeric	O
subunits	I:C0599220
into	O
ordered	O
β-	O
sheet	I:C0162806
oligomers	O
and	O
fibrils	O
.	O

Alzheimer	O
's	I:C0002395
disease	I:C0002395
(	O
Alzheimer	O
's	I:C0002395
disease	I:C0002395
)	O
is	O
the	O
most	O
abundant	O
tauopathy	O
and	O
is	O
characterized	O
by	O
Aβ	O
-	O
derived	O
plaques	O
and	O
tau	B:C0085401
-	O
derived	O
tangles	O
,	O
resulting	O
from	O
the	O
unfolding	O
of	O
the	O
corresponding	O
monomeric	O
subunits	I:C0599220
into	O
ordered	O
β-	O
sheet	I:C0162806
oligomers	O
and	O
fibrils	O
.	O

Alzheimer	O
's	I:C0002395
disease	I:C0002395
(	O
Alzheimer	O
's	I:C0002395
disease	I:C0002395
)	O
is	O
the	O
most	O
abundant	O
tauopathy	O
and	O
is	O
characterized	O
by	O
Aβ	O
-	O
derived	O
plaques	O
and	O
tau	O
-	O
derived	O
tangles	B:C0085400
,	O
resulting	O
from	O
the	O
unfolding	O
of	O
the	O
corresponding	O
monomeric	O
subunits	I:C0599220
into	O
ordered	O
β-	O
sheet	I:C0162806
oligomers	O
and	O
fibrils	O
.	O

Alzheimer	O
's	I:C0002395
disease	I:C0002395
(	O
Alzheimer	O
's	I:C0002395
disease	I:C0002395
)	O
is	O
the	O
most	O
abundant	O
tauopathy	O
and	O
is	O
characterized	O
by	O
Aβ	O
-	O
derived	O
plaques	O
and	O
tau	O
-	O
derived	O
tangles	O
,	O
resulting	O
from	O
the	O
unfolding	B:C1655065
of	O
the	O
corresponding	O
monomeric	O
subunits	I:C0599220
into	O
ordered	O
β-	O
sheet	I:C0162806
oligomers	O
and	O
fibrils	O
.	O

Alzheimer	O
's	I:C0002395
disease	I:C0002395
(	O
Alzheimer	O
's	I:C0002395
disease	I:C0002395
)	O
is	O
the	O
most	O
abundant	O
tauopathy	O
and	O
is	O
characterized	O
by	O
Aβ	O
-	O
derived	O
plaques	O
and	O
tau	O
-	O
derived	O
tangles	O
,	O
resulting	O
from	O
the	O
unfolding	O
of	O
the	O
corresponding	O
monomeric	B:C0599220
subunits	I:C0599220
into	O
ordered	O
β-	O
sheet	I:C0162806
oligomers	O
and	O
fibrils	O
.	O

Alzheimer	O
's	I:C0002395
disease	I:C0002395
(	O
Alzheimer	O
's	I:C0002395
disease	I:C0002395
)	O
is	O
the	O
most	O
abundant	O
tauopathy	O
and	O
is	O
characterized	O
by	O
Aβ	O
-	O
derived	O
plaques	O
and	O
tau	O
-	O
derived	O
tangles	O
,	O
resulting	O
from	O
the	O
unfolding	O
of	O
the	O
corresponding	O
monomeric	O
subunits	I:C0599220
into	O
ordered	O
β-	B:C0162806
sheet	I:C0162806
oligomers	O
and	O
fibrils	O
.	O

Alzheimer	O
's	I:C0002395
disease	I:C0002395
(	O
Alzheimer	O
's	I:C0002395
disease	I:C0002395
)	O
is	O
the	O
most	O
abundant	O
tauopathy	O
and	O
is	O
characterized	O
by	O
Aβ	O
-	O
derived	O
plaques	O
and	O
tau	O
-	O
derived	O
tangles	O
,	O
resulting	O
from	O
the	O
unfolding	O
of	O
the	O
corresponding	O
monomeric	O
subunits	I:C0599220
into	O
ordered	O
β-	O
sheet	I:C0162806
oligomers	O
and	O
fibrils	B:C0225328
.	O

Intervening	B:C0184661
in	O
the	O
toxic	O
aggregation	O
process	O
is	O
a	O
promising	O
therapeutic	O
approach	I:C0087111
,	O
but	O
,	O
to	O
date	O
,	O
a	O
disease	O
-	O
modifying	O
therapy	O
is	O
neither	O
available	O
for	O
Alzheimer	O
's	I:C0002395
disease	I:C0002395
nor	O
for	O
other	O
tauopathies	O
.	O

Intervening	O
in	O
the	O
toxic	O
aggregation	B:C3850147
process	O
is	O
a	O
promising	O
therapeutic	O
approach	I:C0087111
,	O
but	O
,	O
to	O
date	O
,	O
a	O
disease	O
-	O
modifying	O
therapy	O
is	O
neither	O
available	O
for	O
Alzheimer	O
's	I:C0002395
disease	I:C0002395
nor	O
for	O
other	O
tauopathies	O
.	O

Intervening	O
in	O
the	O
toxic	O
aggregation	O
process	O
is	O
a	O
promising	O
therapeutic	B:C0087111
approach	I:C0087111
,	O
but	O
,	O
to	O
date	O
,	O
a	O
disease	O
-	O
modifying	O
therapy	O
is	O
neither	O
available	O
for	O
Alzheimer	O
's	I:C0002395
disease	I:C0002395
nor	O
for	O
other	O
tauopathies	O
.	O

Intervening	O
in	O
the	O
toxic	O
aggregation	O
process	O
is	O
a	O
promising	O
therapeutic	O
approach	I:C0087111
,	O
but	O
,	O
to	O
date	O
,	O
a	O
disease	B:C0012634
-	O
modifying	O
therapy	O
is	O
neither	O
available	O
for	O
Alzheimer	O
's	I:C0002395
disease	I:C0002395
nor	O
for	O
other	O
tauopathies	O
.	O

Intervening	O
in	O
the	O
toxic	O
aggregation	O
process	O
is	O
a	O
promising	O
therapeutic	O
approach	I:C0087111
,	O
but	O
,	O
to	O
date	O
,	O
a	O
disease	O
-	O
modifying	O
therapy	B:C0087111
is	O
neither	O
available	O
for	O
Alzheimer	O
's	I:C0002395
disease	I:C0002395
nor	O
for	O
other	O
tauopathies	O
.	O

Intervening	O
in	O
the	O
toxic	O
aggregation	O
process	O
is	O
a	O
promising	O
therapeutic	O
approach	I:C0087111
,	O
but	O
,	O
to	O
date	O
,	O
a	O
disease	O
-	O
modifying	O
therapy	O
is	O
neither	O
available	O
for	O
Alzheimer	B:C0002395
's	I:C0002395
disease	I:C0002395
nor	O
for	O
other	O
tauopathies	O
.	O

Intervening	O
in	O
the	O
toxic	O
aggregation	O
process	O
is	O
a	O
promising	O
therapeutic	O
approach	I:C0087111
,	O
but	O
,	O
to	O
date	O
,	O
a	O
disease	O
-	O
modifying	O
therapy	O
is	O
neither	O
available	O
for	O
Alzheimer	O
's	I:C0002395
disease	I:C0002395
nor	O
for	O
other	O
tauopathies	B:C0949664
.	O

Along	O
these	O
lines	O
,	O
we	O
have	O
previously	O
demonstrated	O
that	O
a	O
small	O
naphthoquinone	B:C3711678
-	I:C3711678
tryptophan	I:C3711678
hybrid	I:C3711678
,	O
termed	O
NQTrp	O
,	O
is	O
an	O
effective	O
modulator	O
of	O
tauopathy	O
in	O
vitro	O
and	O
in	O
vivo	I:C1515655
.	O

Along	O
these	O
lines	O
,	O
we	O
have	O
previously	O
demonstrated	O
that	O
a	O
small	O
naphthoquinone	O
-	I:C3711678
tryptophan	I:C3711678
hybrid	I:C3711678
,	O
termed	O
NQTrp	B:C3711678
,	O
is	O
an	O
effective	O
modulator	O
of	O
tauopathy	O
in	O
vitro	O
and	O
in	O
vivo	I:C1515655
.	O

Along	O
these	O
lines	O
,	O
we	O
have	O
previously	O
demonstrated	O
that	O
a	O
small	O
naphthoquinone	O
-	I:C3711678
tryptophan	I:C3711678
hybrid	I:C3711678
,	O
termed	O
NQTrp	O
,	O
is	O
an	O
effective	O
modulator	O
of	O
tauopathy	B:C0949664
in	O
vitro	O
and	O
in	O
vivo	I:C1515655
.	O

Along	O
these	O
lines	O
,	O
we	O
have	O
previously	O
demonstrated	O
that	O
a	O
small	O
naphthoquinone	O
-	I:C3711678
tryptophan	I:C3711678
hybrid	I:C3711678
,	O
termed	O
NQTrp	O
,	O
is	O
an	O
effective	O
modulator	O
of	O
tauopathy	O
in	O
vitro	O
and	O
in	B:C1515655
vivo	I:C1515655
.	O

However	O
,	O
NQTrp	B:C3711678
is	O
difficult	O
to	O
synthesize	O
and	O
is	O
not	O
very	I:C0443343
stable	I:C0443343
.	O

However	O
,	O
NQTrp	O
is	O
difficult	O
to	O
synthesize	O
and	O
is	O
not	B:C0443343
very	I:C0443343
stable	I:C0443343
.	O

Therefore	O
,	O
we	O
tested	O
whether	O
a	O
more	O
stable	O
and	O
easier	O
-	O
to	O
-	O
synthesize	O
modified	O
version	O
of	O
NQTrp	B:C3711678
,	O
containing	O
a	O
Cl	O
ion	I:C0596019
,	O
namely	O
Cl	O
-	I:C3501592
NQTrp	I:C3501592
,	O
is	O
also	O
an	O
effective	O
inhibitor	O
of	O
tau	O
aggregation	O
in	O
vitro	O
and	O
in	O
vivo	I:C1515655
.	O

Therefore	O
,	O
we	O
tested	O
whether	O
a	O
more	O
stable	O
and	O
easier	O
-	O
to	O
-	O
synthesize	O
modified	O
version	O
of	O
NQTrp	O
,	O
containing	O
a	O
Cl	B:C0596019
ion	I:C0596019
,	O
namely	O
Cl	O
-	I:C3501592
NQTrp	I:C3501592
,	O
is	O
also	O
an	O
effective	O
inhibitor	O
of	O
tau	O
aggregation	O
in	O
vitro	O
and	O
in	O
vivo	I:C1515655
.	O

Therefore	O
,	O
we	O
tested	O
whether	O
a	O
more	O
stable	O
and	O
easier	O
-	O
to	O
-	O
synthesize	O
modified	O
version	O
of	O
NQTrp	O
,	O
containing	O
a	O
Cl	O
ion	I:C0596019
,	O
namely	O
Cl	B:C3501592
-	I:C3501592
NQTrp	I:C3501592
,	O
is	O
also	O
an	O
effective	O
inhibitor	O
of	O
tau	O
aggregation	O
in	O
vitro	O
and	O
in	O
vivo	I:C1515655
.	O

Therefore	O
,	O
we	O
tested	O
whether	O
a	O
more	O
stable	O
and	O
easier	O
-	O
to	O
-	O
synthesize	O
modified	O
version	O
of	O
NQTrp	O
,	O
containing	O
a	O
Cl	O
ion	I:C0596019
,	O
namely	O
Cl	O
-	I:C3501592
NQTrp	I:C3501592
,	O
is	O
also	O
an	O
effective	O
inhibitor	O
of	O
tau	B:C0085401
aggregation	O
in	O
vitro	O
and	O
in	O
vivo	I:C1515655
.	O

Therefore	O
,	O
we	O
tested	O
whether	O
a	O
more	O
stable	O
and	O
easier	O
-	O
to	O
-	O
synthesize	O
modified	O
version	O
of	O
NQTrp	O
,	O
containing	O
a	O
Cl	O
ion	I:C0596019
,	O
namely	O
Cl	O
-	I:C3501592
NQTrp	I:C3501592
,	O
is	O
also	O
an	O
effective	O
inhibitor	O
of	O
tau	O
aggregation	B:C3850147
in	O
vitro	O
and	O
in	O
vivo	I:C1515655
.	O

Therefore	O
,	O
we	O
tested	O
whether	O
a	O
more	O
stable	O
and	O
easier	O
-	O
to	O
-	O
synthesize	O
modified	O
version	O
of	O
NQTrp	O
,	O
containing	O
a	O
Cl	O
ion	I:C0596019
,	O
namely	O
Cl	O
-	I:C3501592
NQTrp	I:C3501592
,	O
is	O
also	O
an	O
effective	O
inhibitor	O
of	O
tau	O
aggregation	O
in	O
vitro	O
and	O
in	B:C1515655
vivo	I:C1515655
.	O

Cl	B:C3501592
-	I:C3501592
NQTrp	I:C3501592
was	O
previously	O
shown	O
to	O
efficiently	O
inhibit	O
the	O
aggregation	O
of	O
various	O
amyloidogenic	O
proteins	I:C1456454
and	O
peptides	O
.	O

Cl	O
-	I:C3501592
NQTrp	I:C3501592
was	O
previously	O
shown	O
to	O
efficiently	O
inhibit	O
the	O
aggregation	B:C3850147
of	O
various	O
amyloidogenic	O
proteins	I:C1456454
and	O
peptides	O
.	O

Cl	O
-	I:C3501592
NQTrp	I:C3501592
was	O
previously	O
shown	O
to	O
efficiently	O
inhibit	O
the	O
aggregation	O
of	O
various	O
amyloidogenic	B:C1456454
proteins	I:C1456454
and	O
peptides	O
.	O

Cl	O
-	I:C3501592
NQTrp	I:C3501592
was	O
previously	O
shown	O
to	O
efficiently	O
inhibit	O
the	O
aggregation	O
of	O
various	O
amyloidogenic	O
proteins	I:C1456454
and	O
peptides	B:C0030956
.	O

We	O
demonstrate	O
that	O
Cl	B:C3501592
-	I:C3501592
NQTrp	I:C3501592
inhibits	O
the	O
in	O
vitro	O
assembly	O
of	O
PHF6	O
,	O
the	O
aggregation	O
-	O
prone	O
fragment	O
of	O
tau	O
,	O
and	O
alleviates	O
tauopathy	O
symptoms	O
in	O
a	O
transgenic	O
Drosophila	O
model	O
through	O
the	O
inhibition	O
of	O
tau	O
aggregation	O
-	O
engendered	O
toxicity	O
.	O

We	O
demonstrate	O
that	O
Cl	O
-	I:C3501592
NQTrp	I:C3501592
inhibits	O
the	O
in	O
vitro	O
assembly	O
of	O
PHF6	B:C1335533
,	O
the	O
aggregation	O
-	O
prone	O
fragment	O
of	O
tau	O
,	O
and	O
alleviates	O
tauopathy	O
symptoms	O
in	O
a	O
transgenic	O
Drosophila	O
model	O
through	O
the	O
inhibition	O
of	O
tau	O
aggregation	O
-	O
engendered	O
toxicity	O
.	O

We	O
demonstrate	O
that	O
Cl	O
-	I:C3501592
NQTrp	I:C3501592
inhibits	O
the	O
in	O
vitro	O
assembly	O
of	O
PHF6	O
,	O
the	O
aggregation	B:C3850147
-	O
prone	O
fragment	O
of	O
tau	O
,	O
and	O
alleviates	O
tauopathy	O
symptoms	O
in	O
a	O
transgenic	O
Drosophila	O
model	O
through	O
the	O
inhibition	O
of	O
tau	O
aggregation	O
-	O
engendered	O
toxicity	O
.	O

We	O
demonstrate	O
that	O
Cl	O
-	I:C3501592
NQTrp	I:C3501592
inhibits	O
the	O
in	O
vitro	O
assembly	O
of	O
PHF6	O
,	O
the	O
aggregation	O
-	O
prone	O
fragment	B:C1335533
of	O
tau	O
,	O
and	O
alleviates	O
tauopathy	O
symptoms	O
in	O
a	O
transgenic	O
Drosophila	O
model	O
through	O
the	O
inhibition	O
of	O
tau	O
aggregation	O
-	O
engendered	O
toxicity	O
.	O

We	O
demonstrate	O
that	O
Cl	O
-	I:C3501592
NQTrp	I:C3501592
inhibits	O
the	O
in	O
vitro	O
assembly	O
of	O
PHF6	O
,	O
the	O
aggregation	O
-	O
prone	O
fragment	O
of	O
tau	B:C0085401
,	O
and	O
alleviates	O
tauopathy	O
symptoms	O
in	O
a	O
transgenic	O
Drosophila	O
model	O
through	O
the	O
inhibition	O
of	O
tau	O
aggregation	O
-	O
engendered	O
toxicity	O
.	O

We	O
demonstrate	O
that	O
Cl	O
-	I:C3501592
NQTrp	I:C3501592
inhibits	O
the	O
in	O
vitro	O
assembly	O
of	O
PHF6	O
,	O
the	O
aggregation	O
-	O
prone	O
fragment	O
of	O
tau	O
,	O
and	O
alleviates	O
tauopathy	B:C0949664
symptoms	O
in	O
a	O
transgenic	O
Drosophila	O
model	O
through	O
the	O
inhibition	O
of	O
tau	O
aggregation	O
-	O
engendered	O
toxicity	O
.	O

We	O
demonstrate	O
that	O
Cl	O
-	I:C3501592
NQTrp	I:C3501592
inhibits	O
the	O
in	O
vitro	O
assembly	O
of	O
PHF6	O
,	O
the	O
aggregation	O
-	O
prone	O
fragment	O
of	O
tau	O
,	O
and	O
alleviates	O
tauopathy	O
symptoms	B:C1457887
in	O
a	O
transgenic	O
Drosophila	O
model	O
through	O
the	O
inhibition	O
of	O
tau	O
aggregation	O
-	O
engendered	O
toxicity	O
.	O

We	O
demonstrate	O
that	O
Cl	O
-	I:C3501592
NQTrp	I:C3501592
inhibits	O
the	O
in	O
vitro	O
assembly	O
of	O
PHF6	O
,	O
the	O
aggregation	O
-	O
prone	O
fragment	O
of	O
tau	O
,	O
and	O
alleviates	O
tauopathy	O
symptoms	O
in	O
a	O
transgenic	B:C0003069
Drosophila	O
model	O
through	O
the	O
inhibition	O
of	O
tau	O
aggregation	O
-	O
engendered	O
toxicity	O
.	O

We	O
demonstrate	O
that	O
Cl	O
-	I:C3501592
NQTrp	I:C3501592
inhibits	O
the	O
in	O
vitro	O
assembly	O
of	O
PHF6	O
,	O
the	O
aggregation	O
-	O
prone	O
fragment	O
of	O
tau	O
,	O
and	O
alleviates	O
tauopathy	O
symptoms	O
in	O
a	O
transgenic	O
Drosophila	B:C0013138
model	O
through	O
the	O
inhibition	O
of	O
tau	O
aggregation	O
-	O
engendered	O
toxicity	O
.	O

We	O
demonstrate	O
that	O
Cl	O
-	I:C3501592
NQTrp	I:C3501592
inhibits	O
the	O
in	O
vitro	O
assembly	O
of	O
PHF6	O
,	O
the	O
aggregation	O
-	O
prone	O
fragment	O
of	O
tau	O
,	O
and	O
alleviates	O
tauopathy	O
symptoms	O
in	O
a	O
transgenic	O
Drosophila	O
model	B:C1519606
through	O
the	O
inhibition	O
of	O
tau	O
aggregation	O
-	O
engendered	O
toxicity	O
.	O

We	O
demonstrate	O
that	O
Cl	O
-	I:C3501592
NQTrp	I:C3501592
inhibits	O
the	O
in	O
vitro	O
assembly	O
of	O
PHF6	O
,	O
the	O
aggregation	O
-	O
prone	O
fragment	O
of	O
tau	O
,	O
and	O
alleviates	O
tauopathy	O
symptoms	O
in	O
a	O
transgenic	O
Drosophila	O
model	O
through	O
the	O
inhibition	O
of	O
tau	B:C0085401
aggregation	O
-	O
engendered	O
toxicity	O
.	O

We	O
demonstrate	O
that	O
Cl	O
-	I:C3501592
NQTrp	I:C3501592
inhibits	O
the	O
in	O
vitro	O
assembly	O
of	O
PHF6	O
,	O
the	O
aggregation	O
-	O
prone	O
fragment	O
of	O
tau	O
,	O
and	O
alleviates	O
tauopathy	O
symptoms	O
in	O
a	O
transgenic	O
Drosophila	O
model	O
through	O
the	O
inhibition	O
of	O
tau	O
aggregation	B:C3850147
-	O
engendered	O
toxicity	O
.	O

We	O
demonstrate	O
that	O
Cl	O
-	I:C3501592
NQTrp	I:C3501592
inhibits	O
the	O
in	O
vitro	O
assembly	O
of	O
PHF6	O
,	O
the	O
aggregation	O
-	O
prone	O
fragment	O
of	O
tau	O
,	O
and	O
alleviates	O
tauopathy	O
symptoms	O
in	O
a	O
transgenic	O
Drosophila	O
model	O
through	O
the	O
inhibition	O
of	O
tau	O
aggregation	O
-	O
engendered	O
toxicity	B:C0600688
.	O

These	O
results	O
suggest	O
that	O
Cl	B:C3501592
-	I:C3501592
NQTrp	I:C3501592
could	O
be	O
a	O
unique	O
potential	O
therapeutic	O
for	O
Alzheimer	O
's	I:C0002395
disease	I:C0002395
since	O
it	O
targets	O
aggregation	O
of	O
both	O
Aβ	O
and	O
tau	O
.	O

These	O
results	O
suggest	O
that	O
Cl	O
-	I:C3501592
NQTrp	I:C3501592
could	O
be	O
a	O
unique	O
potential	O
therapeutic	O
for	O
Alzheimer	B:C0002395
's	I:C0002395
disease	I:C0002395
since	O
it	O
targets	O
aggregation	O
of	O
both	O
Aβ	O
and	O
tau	O
.	O

These	O
results	O
suggest	O
that	O
Cl	O
-	I:C3501592
NQTrp	I:C3501592
could	O
be	O
a	O
unique	O
potential	O
therapeutic	O
for	O
Alzheimer	O
's	I:C0002395
disease	I:C0002395
since	O
it	O
targets	O
aggregation	B:C3850147
of	O
both	O
Aβ	O
and	O
tau	O
.	O

These	O
results	O
suggest	O
that	O
Cl	O
-	I:C3501592
NQTrp	I:C3501592
could	O
be	O
a	O
unique	O
potential	O
therapeutic	O
for	O
Alzheimer	O
's	I:C0002395
disease	I:C0002395
since	O
it	O
targets	O
aggregation	O
of	O
both	O
Aβ	O
and	O
tau	B:C0085401
.	O

